BRAF and colorectal carcinoma: In contrast, the TRICE study exclusively enrolled RAS/BRAF wild-type CRC patients with technically unresectable CRLM, aiming to evaluate the efficacy of cetuximab in combination with an intensified chemotherapy backbone in CRC patients who could potentially achieve conversion to resection.